Spero Therapeutics to Announce Q1 2024 Financial Results and Business Update on May 15, 2024

CAMBRIDGE, Mass., May 08, 2024 – Spero Therapeutics, Inc. (Nasdaq: SPRO), a biopharmaceutical company dedicated to developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, has announced its plan to release financial results for the first quarter of 2024 on May 15, following market closure. The company also plans to provide an update on its business and current research pipeline. However, Spero Therapeutics will not be holding a conference call for this update and intends to resume its quarterly earnings calls with its second quarter 2024 results announcement.

Spero Therapeutics, based in Cambridge, Massachusetts, is committed to advancing treatments for rare diseases and MDR bacterial infections. The company is currently focused on the development of its leading product candidate, SPR720. This candidate is an oral treatment designed for nontuberculous mycobacterial pulmonary disease (NTM-PD), a rare lung condition caused by non-tuberculous mycobacterial infections. SPR720 is currently undergoing a Phase 2A proof of concept study to determine its effectiveness and safety.

Additionally, Spero Therapeutics is progressing with tebipenem HBr, an investigational oral drug aimed at treating complicated urinary tract infections (cUTI), including pyelonephritis. This drug is in Phase 3 of its registrational trial. Spero Therapeutics has granted GSK an exclusive license to commercialize tebipenem HBr globally, excluding certain Asian territories.

Another significant product in Spero’s pipeline is SPR206. This investigational drug is an innovative, IV-administered direct-acting next-generation polymyxin. It has demonstrated significant antibiotic activity against MDR Gram-negative pathogens, such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in preclinical studies. The FDA has cleared an Investigational New Drug (IND) application for SPR206, allowing it to move forward into a Phase 2 clinical trial. This trial will focus on patients suffering from hospital-acquired or ventilator-associated bacterial pneumonia.